News | Quality Assurance (QA) | September 16, 2019

Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

Company will highlight new tools for workflow automation and emergent techniques

Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

September 16, 2019 — At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear Corp. will present novel advancements in radiation oncology quality management.

For the SunCheck Quality Management Platform, Sun Nuclear introduces PlanCheck. This new module within the SunCheck Patient workflow automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent. At ASTRO 2019, Sun Nuclear will also highlight SunCheck's expanded direct device integration, plus support for Varian Halcyon System secondary dose calculations, pre-treatment quality assurance (QA) and in-vivo monitoring.

Sun Nuclear will also introduce new Precision Laser Systems for positron emission tomography/computed tomography (PET/CT) simulation, magnetic resonance (MR) simulation, MR-guided radiotherapy (RT) and linear accelerator (linac)-based RT. Redesigned to better fit clinical workflows, CT SIM+ and MICRO+ laser systems offer high precision and accuracy at the patient, with what the company calls unmatched reliability, laser line definition and laser line length. Compatible with all major third-party systems, CT SIM+ software provides automation for enhanced patient focus.  

Beyond workflow automation support, Sun Nuclear enables adoption of emergent treatment techniques, including stereotactic radiosurgery (SRS) and MR-guided radiation therapy (MRgRT).

Enhancing the Sun Nuclear SRS QA portfolio is the introduction of the MultiMet-WL Cube. The device quantifies the margin of error for off-axis SRS targets, measuring error margins for single-isocenter multiple metastases treatments. Further supporting SRS programs are advancements with SRS MapCheck, including support for the Accuray CyberKnife System and vertex fields, including HyperArc. 

Sun Nuclear addresses the challenges of MRgRT with a suite of solutions, including ArcCheck-MR and IC Profiler-MR. Available soon and on display at ASTRO, Daily QA-MR will become the first commercially available daily QA system for MR-linacs.

For more information: www.sunnuclear.com

Related Content

A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...